In conclusion, this study identifies <i>JUN</i> and C3 as candidate biomarkers associated with CKD and suggests Resveratrol as a promising preclinical intervention candidate targeting the MAPK/JNK-c-Jun axis, providing preliminary computational and preclinical evidence for biomarker discovery and natural medicine-based intervention in CKD. The gene discussed is MAPK8; the disease is chronic kidney disease.